MRNA vs PFE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
PFE is the larger of the two ($156.92B market cap): the incumbent the market prices for continued execution (9.32x forward earnings, beta 0.30). MRNA is the smaller challenger ($79.58B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, MRNA fits: analysts expect its revenue to rise 11% next year, against a 4% decline for PFE. If you believe in profit, PFE fits: it is expected to make money next year (9.32x forward earnings), while MRNA is still expected to post a loss.
MRNA vs PFE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MRNA | PFE | What it tells you |
|---|---|---|---|
| Market cap | $79.58B | $156.92B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -46.96 | 9.32 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.17 | 0.30 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 67% of range | 50% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 11.62 | 1.76 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how MRNA and PFE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MRNA and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MRNA and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Moderna (MRNA) do?
Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.
What does Pfizer (PFE) do?
Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.
MRNA vs PFE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
- PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.
MRNA or PFE: which should you pick?
If the story you believe is MRNA's (Respiratory franchise beyond COVID), MRNA is the more direct way to own it; if it is PFE's (Oncology expansion via Seagen), PFE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MRNA and PFE guides.
MRNA vs PFE: the full fundamentals
MRNA. MRNA trades on pipeline potential rather than current earnings: it is loss-making over the trailing year, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 538% year to date to roughly 32 times trailing sales after the August Phase 3 melanoma success, even after a 17% drop on higher spending guidance in November. The 19 analysts Yahoo Finance tracks have a mean target near $165, under the $196.74 close, and consensus sees a loss of about $4.45 per share in 2027 on about $2.69 billion of revenue.
PFE. At about $27.54 (November 20, 2026) Pfizer trades at about 9x forward earnings with a dividend yield near 6.3%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges, including a GAAP loss in Q2 2026, rather than weak operations. After pulling back from its early-November high the stock sits below the 26 analysts' mean target of about $30.22 (an average buy rating), so the valuation balances substantial cash generation against flat-to-lower consensus earnings.
Headline figures (approximate, November 2026): MRNA shows market cap ~$80 billion, revenue (ttm) ~$2.5 billion, q3 2026 revenue ~$1.31 billion vs ~$892 million consensus, net income (ttm) ~-$2.8 billion; PFE shows revenue (ttm) ~$63.6 billion (Q3 2026 ~flat YoY), operating margin ~29%, net income (ttm, gaap) ~$4.0 billion, q3 2026 adjusted eps ~$0.87 vs ~$0.74 consensus.
The bottom line: MRNA vs PFE
MRNA and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined MRNA and PFE exposure against your real portfolio. It is not an investment adviser.
Wondering how MRNA or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Moderna
Ask Walnut's AI anything about MRNA and see how it fits what you own.
FAQ
What is the difference between MRNA and PFE?
+
Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MRNA or PFE the better stock?
+
Neither is universally better. PFE is the larger incumbent; MRNA is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MRNA or PFE?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MRNA and PFE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MRNA vs PFE?
+
MRNA: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed. Valuation risk is now acute: at about $80 billion the company trades near 32 times trailing sales, and the 19 analysts Yahoo Finance tracks have a mean target near $165 with a Hold rating, below the November 20 close (Jefferies cut its target to $215 from $230 on November 18). Higher spending is a newer risk: guidance for about $4 billion of 2027 cash costs sent the shares down about 17% in a week in November 2026, and debt has risen to about $4.2 billion. A delayed FDA filing or a regulatory setback for intismeran could reverse much of the gain. Walnut is not an investment adviser. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of November 2026 has revenue of about $63.1 billion in 2026 slipping to $60.8 billion in 2027, with EPS of roughly $3.05 and $2.95, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.4 billion against $14.3 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout near 246% of trailing GAAP EPS of about $0.70), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MRNA or PFE; figures are approximate and dated (as of November 2026). Verify current data before investing.